Department of Medicine, University of California, San Diego, and San Diego Veteran's Affairs Medical Center, La Jolla, California, USA.
Am J Rhinol Allergy. 2011 Nov-Dec;25(6):373-8. doi: 10.2500/ajra.2011.25.3661.
Laryngeal angioedema may be associated with significant morbidity and even mortality. Because of the potential severity of attacks, both allergists and otolaryngologists must be knowledgeable about the recognition and treatment of laryngeal angioedema. This study describes the clinical characteristics and pathophysiology of bradykinin-mediated angioedema.
A literature review was conducted concerning the clinical characteristics and pathophysiology of types I and II hereditary angioedema (HAE), type III HAE, acquired C1 inhibitor (C1INH) deficiency, and angiotensin-converting enzyme (ACE) inhibitor-associated angioedema.
The diagnosis of type I/II HAE is relatively straightforward as long as the clinician maintains a high index of suspicion. Mutations in the SERPING1 gene result in decreased secretion of functional C1INH and episodic activation of plasma kallikrein and Hageman factor (FXII) of the plasma contact system with cleavage of high molecular weight kininogen and generation of bradykinin. In contrast, there are no unequivocal criteria for making a diagnosis of type III HAE, although a minority of these patients may have a mutation in the factor XII gene. Angioedema attacks and mediator of swelling in acquired C1INH deficiency are similar to those in type I or II HAE; however, it occurs on a sporadic basis because of excessive consumption of C1INH in patients who are middle aged or older. ACE inhibitor-associated angioedema should always be considered in any patient taking an ACE inhibitor who experiences angioedema. ACE is a kininase, which when inhibited is thought to result in increased bradykinin levels. Bradykinin acts on vascular endothelial cells to enhance vascular permeability.
Laryngeal swelling is not infrequently encountered in bradykinin-mediated angioedema. Novel therapies are becoming available that for the first time provide effective treatment for bradykinin-mediated angioedema. Because the characteristics and treatment of these angioedemas are quite distinct from each other and from histamine-mediated angioedema, it is crucial that the physician be able to recognize and distinguish these swelling disorders.
喉部血管性水肿可能与显著的发病率甚至死亡率有关。由于发作的潜在严重性,变态反应学家和耳鼻喉科医生都必须了解识别和治疗喉部血管性水肿。本研究描述了缓激肽介导的血管性水肿的临床特征和病理生理学。
对 I 型和 II 型遗传性血管性水肿(HAE)、III 型 HAE、获得性 C1 抑制剂(C1INH)缺乏症和血管紧张素转换酶(ACE)抑制剂相关血管性水肿的临床特征和病理生理学进行文献回顾。
只要临床医生保持高度怀疑,I/II 型 HAE 的诊断相对简单。SERPING1 基因突变导致功能性 C1INH 分泌减少,并间歇性激活血浆激肽释放酶和血浆接触系统的 Hageman 因子(FXII),裂解高分子量激肽原并产生缓激肽。相比之下,III 型 HAE 没有明确的诊断标准,尽管少数这些患者可能存在因子 XII 基因突变。获得性 C1INH 缺乏症中的血管性水肿发作和肿胀介质与 I 型或 II 型 HAE 相似;然而,由于中年或老年患者 C1INH 过度消耗,它以散发性为特征。任何服用 ACE 抑制剂并发生血管性水肿的患者都应始终考虑 ACE 抑制剂相关血管性水肿。ACE 是一种激肽酶,当被抑制时,被认为会导致缓激肽水平升高。缓激肽作用于血管内皮细胞,增强血管通透性。
缓激肽介导的血管性水肿并不少见。新的治疗方法正在出现,首次为缓激肽介导的血管性水肿提供有效治疗。由于这些血管性水肿的特征和治疗与组胺介导的血管性水肿截然不同,医生能够识别和区分这些肿胀障碍至关重要。